Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy

被引:44
作者
Abduljalil, Khaled [1 ]
Pansari, Amita [1 ]
Jamei, Masoud [1 ]
机构
[1] Certara UK Ltd, Simcyp Div, Level 2 Acero,1 Concourse Way, Sheffield S1 2BJ, S Yorkshire, England
关键词
Pregnancy; PBPK; Pharmacokinetics; Inter-individual variability; NIFEDIPINE PHARMACOKINETICS; STEREOSELECTIVE METABOLISM; ABSOLUTE BIOAVAILABILITY; DRUG-METABOLISM; AMNIOTIC-FLUID; PBPK MODEL; PROPRANOLOL; METOPROLOL; CAFFEINE; DISPOSITION;
D O I
10.1007/s10928-020-09711-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Concerns over gestational effects on the disposition of drugs has highlighted the need for a better understanding of drug distribution and elimination during pregnancy. This study aimed at predicting maternal drug kinetics using a physiologically based pharmacokinetic (PBPK) modelling approach focusing on the observed gestational changes in three important Cytochrome P450 metabolizing enzymes, namely, CYP1A2, CYP2D6 and CYP3A4 at different gestational weeks (GWs). The Pregnancy PBPK model within the Simcyp Simulator V19 was used to predict the pharmacokinetics of sensitive probes to these enzymes; namely caffeine, theophylline, metoprolol, propranolol, paroxetine, midazolam, nifedipine and rilpivirine. PBPK model predictions were compared against clinical data collated from multiple studies for each compound to cover a wide spectrum of gestational ages. Pregnancy PBPK model predictions were within 2-fold error and indicated that CYP1A2 activity is approximately 0.70, 0.44 and 0.30 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. On the other hand, CYP2D6 activity increases by 1.36, 2.16 and 3.10 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. Likewise, CYP3A4 activity increases by 1.25, 1.75 and 2.32 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. The enzymes activity have been qualified throughout pregnancy. Quantified changes in drug dosing are most relevant during the third trimester, especially for drugs that are mainly eliminated by CYP1A2, CYP2D6 and CYP3A4 enzymes. The provided functions describing the continuous changes to the activity of these enzymes during pregnancy are important when modelling long term pharmacokinetic studies where longitudinal modelling or time-varying covariates are used.
引用
收藏
页码:361 / 383
页数:23
相关论文
共 74 条
[1]   Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models [J].
Abduljalil, Khaled ;
Badhan, Raj K. Singh .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (04) :319-340
[2]   Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population [J].
Abduljalil, Khaled ;
Pan, Xian ;
Pansari, Amita ;
Jamei, Masoud ;
Johnson, Trevor N. .
CLINICAL PHARMACOKINETICS, 2020, 59 (04) :501-518
[3]   Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model [J].
Abduljalil, Khaled ;
Jamei, Masoud ;
Rostami-Hodjegan, Amin ;
Johnson, Trevor N. .
AAPS JOURNAL, 2014, 16 (03) :568-576
[4]   Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyA Database for Parameters Required in Physiologically Based Pharmacokinetic Modelling [J].
Khaled Abduljalil ;
Penny Furness ;
Trevor N. Johnson ;
Amin Rostami-Hodjegan ;
Hora Soltani .
Clinical Pharmacokinetics, 2012, 51 (6) :365-396
[5]  
ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310
[6]   Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients [J].
Antunes, Natalicia de Jesus ;
Cavalli, Ricardo Carvalho ;
Marques, Maria Paula ;
Dantas Moises, Elaine Christine ;
Lanchote, Vera Lucia .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) :605-616
[7]   MIDAZOLAM KINETICS IN WOMEN OF 2 AGE-GROUPS [J].
AVRAM, MJ ;
FRAGEN, RJ ;
CALDWELL, NJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (04) :505-508
[8]   NIFEDIPINE PHARMACOKINETICS AND PHARMACODYNAMICS DURING THE IMMEDIATE POSTPARTUM PERIOD IN PATIENTS WITH PREECLAMPSIA [J].
BARTON, JR ;
PREVOST, RR ;
WILSON, DA ;
WHYBREW, WD ;
SIBAI, BM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (04) :951-954
[9]  
Beierle I, 1999, INT J CLIN PHARM TH, V37, P529
[10]   Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance [J].
Borges, S ;
Li, L ;
Hamman, MA ;
Jones, DR ;
Hall, SD ;
Gorski, JC .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (07) :1052-1055